POPULARITY
This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now! Click here to claim you free CME/NCPD credit: https://bit.ly/3OFBxiX
This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now!
Juan Pablo Alderuccio, MD, assistant professor of medicine in the Division of Hematology, Department of Medicine at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine in Florida, spoke with CancerNetwork® about his review published in the journal ONCOLOGY® titled, Current Treatments in Marginal Zone Lymphoma. In the article, Alderuccio explored current approaches to the diagnosis and treatment of marginal zone lymphoma. He also touched on his strategies for treating localized versus advanced disease and novel emerging strategies clinicians practicing in the community should be aware of. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Marginal Zone Lymphoma CancerCare Connect Education Workshops
Was the Omicron variant more deadly than Delta? Find out this and more in today's PV Roundup podcast.
Was the Omicron variant more deadly than Delta? Find out this and more in today's PV Roundup podcast.
Waldenstrom’s Macroglobulinemia CancerCare Connect Education Workshops
Marginal Zone Lymphoma CancerCare Connect Education Workshops
Marginal Zone Lymphoma CancerCare Connect Education Workshops
In this episode, Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: Follicular lymphomaMarginal zone lymphomaMantle cell lymphomaDiffuse large B-cell lymphomaPosttransplant lymphoproliferative disorderPresenters:Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaBrad S. Kahl, MDProfessor of MedicineDepartment of Medical OncologyWashington University School of MedicineSt Louis, MissouriJohn P. Leonard, MDRichard T. Silver Distinguished Professor of Hematology and Medical OncologyProfessor of MedicineWeill Cornell MedicineNew York Presbyterian HospitalNew York, New YorkLink to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:https://bit.ly/3tb47wU
Marginal Zone Lymphoma CancerCare Connect Education Workshops
What are the long-term cardiovascular outcomes of COVID-19? Find out about this and more in today's PV Roundup podcast.
Experts discuss the role of PI3K inhibitors in R/R follicular and marginal zone lymphoma. Credit available for this activity expires: 11/2/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/961885?src=mkm_podcast_addon_961885
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Listen to a soundcast of the September 14, and 15, 2021, FDA approvals of Brukinsa (zanubrutinib), for relapsed or refractory marginal zone lymphoma, and Exkivity (mobocertinib) for adult patients with locally advanced or metastatic non-small lung cancer.
Marginal Zone Lymphoma CancerCare Connect Education Workshops
Small Lymphocytic Lymphoma CancerCare Connect Education Workshops
Peripheral T-Cell Lymphoma CancerCare Connect Education Workshops
Marginal Zone Lymphoma CancerCare Connect Education Workshops
Cutaneous T-Cell Lymphoma CancerCare Connect Education Workshops
Peripheral T-Cell Lymphoma CancerCare Connect Education Workshops
Marginal Zone Lymphoma CancerCare Connect Education Workshops
Owen A. O'Connor, Chief Scientific Officer at TG Therapeutics, discusses umbralisib, which was approved for the treatment of relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone lymphoma (MZL)
Owen A. O'Connor, Chief Scientific Officer at TG Therapeutics, gives an overview of follicular lymphoma (FL) and marginal zone lymphoma (MZL).